CEO of ViiV Healthcare, Dr Dominique Limet, will step down at the end of March 2017 after seven years at the helm. Deborah Waterhouse, currently Senior Vice President Primary Care, GSK US Pharmaceuticals, will succeed him, and will taking up the CEO Designate role on 1 January 2017.
Ms Waterhouse joined GSK in 1996 and is currently SVP Primary Care in US Pharmaceuticals, prior to which she led the US Vaccines business. She brings a wealth of experience to ViiV Healthcare having lived and worked in Europe, Asia and the USA, and a strong track record of performance in both specialty and primary care. She led the HIV business in the UK before heading the HIV Centre of Excellence for Pharma Europe, and held international roles as General Manager of Australia and New Zealand and SVP Central and Eastern Europe.
After beginning his career as a GP in France, Dr Limet joined Ciba Geigy, where he held various marketing and management positions. He went on to join GSK in 1996, as General Manager of GSK France. He then became SVP, Southern & Eastern Europe Area Director and then Head of GSK Personalised Medicine Strategy.
Andrew Witty, Chief Executive Officer, GSK, said: “Deborah is a dynamic leader who has a real passion to deliver for patients and customers and we are confident that she will continue to develop the business successfully to make a difference for people living with HIV, their families and society as a whole.”
David Redfern, Chairman of ViiV Healthcare, said: “Dominique has been an outstanding leader of ViiV Healthcare. He has helped to create an entirely new company at the forefront of HIV research and treatment development.”
Ms Waterhouse said: “I’m honoured to have the opportunity to lead such an exciting endeavour.”
Cheryl MacDiarmid has been appointed to succeed Ms Waterhouse as SVP US Pharmaceuticals Primary Care.